Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a material event occurring on December 30, 2021. The Company, an emerging growth company incorporated in Delaware, operates in the genomics sector with principal executive offices in San Diego, California.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a new contractual obligation.
Material Changes and Agreements
On December 30, 2021, the Company entered into a Standard Industrial/Commercial Single-Tenant Lease with 6777 Nancy Ridge LLC for approximately 11,978 rentable square feet of laboratory and office space in San Diego, California.
- Lease Term: The Initial Term commenced on December 1, 2021, and expires on January 31, 2026.
- Rent Structure: Base rent is $3.50 per square foot per month, subject to annual upward adjustments of approximately 3.0%.
- Additional Costs: The Company is responsible for operating expenses, utilities, taxes, and insurance.
- Tenant Improvements: The Company is entitled to an allowance of approximately $71,900.
- Renewal Option: One option to extend the lease for 36 months at prevailing market rent, subject to notice requirements.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The primary contingency noted is the Landlord's right to terminate the Lease in the event of a default by the Company on certain obligations.
Investor Verification Checklist
- Verify the total annualized cost of the new lease including base rent and estimated operating expenses.
- Confirm the impact of the $71,900 tenant improvement allowance on the Company's cash flow and capital expenditures.
- Review the full text of the Lease agreement when filed as an exhibit to the Form 10-K for the year ended December 31, 2021.
- Assess whether the new space aligns with the Company's operational capacity and growth strategy.